Skip to main content
SpringerLink
Log in

Hereditary and Acquired Antithrombin Deficiency

Epidemiology, Pathogenesis and Treatment Options

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is growing evidence to suggest that antithrombin also plays a role in the inhibition of inflammation within the environment of the vascular endothelium. Reduced plasma antithrombin may result from congenital deficiency or arise secondarily from a range of disorders such as liver dysfunction, premature infancy and sepsis, or as a result of interventions such as major surgery or cardiopulmonary bypass.

Congenital antithrombin deficiency is the most clinically important of the inherited thrombophilias resulting in thrombosis in the majority of those affected. The challenge in managing these patients is preventing potentially life-threatening thrombosis, while minimising the equally significant risk of haemorrhage associated with long-term anticoagulation. This is achieved in the first instance by identifying high-risk episodes such as surgery, immobility and pregnancy for which prophylactic anticoagulation can be used in the short term. Prophylaxis for such periods is best provided by the use of low molecular weight heparin (LMWH) with substitution by or addition of antithrombin concentrate in particularly high-risk circumstances. In the case of pregnancy, antithrombin concentrate is often used around the time of birth when LMWH may increase the risk of post-partum haemorrhage. As patients with congenital antithrombin deficiency get older so their thrombotic risk gradually increases and for many patients long-term anticoagulation becomes unavoidable because of recurrent episodes of venous thromboembolism.

There has been much interest in the role of antithrombin deficiency in the setting of sepsis and the critically ill patient where there is a clear correlation between severity of illness and degree of antithrombin reduction. It is not clear yet, however, to what extent the depletion of antithrombin affects the clinical condition of such patients. A number of trials have investigated the use of antithrombin as a treatment in the intensive care setting with the overall conclusion being that there is some benefit to its use but only if large supra-physiological doses are used. It has also become clear that the concurrent use of any form of heparin removes whatever benefit may be derived from antithrombin treatment in this setting. Until recently, antithrombin replacement was only available as a pooled plasma-derived product, which despite effective viral inactivation still carries an uncertain risk of transfusion transmitted infection. A recombinant antithrombin product now under investigation, and recently licensed in Europe, may provide a useful alternative treatment option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of trade names is for identification purposes only and does not imply endorsement.

References

  1. Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980 Jul 31; 95(2): 864–71

    Article  PubMed  CAS  Google Scholar 

  2. Yanada M, Kojima T, Ishiguro K, et al. Impact of antithrombin deficiency in thrombogenesis: lipopolysaccharide and stress-induced thrombus formation in heterozygous antithrombindeficient mice. Blood 2002 Apr 1; 99(7): 2455–8

    Article  PubMed  CAS  Google Scholar 

  3. Lane DA, Kunz G, Olds RJ, et al. Molecular genetics of antithrombin deficiency. Blood Rev 1996 Jun; 10(2): 59–74

    Article  PubMed  CAS  Google Scholar 

  4. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002 Nov; 126(11): 1326–36

    PubMed  CAS  Google Scholar 

  5. Walker CPR, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth 2002 Jun; 88(6): 848–63

    Article  PubMed  CAS  Google Scholar 

  6. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24(1): 19–25

    Article  PubMed  CAS  Google Scholar 

  7. Wiedermann CJ, Romisch J. The anti-inflammatory actions of antithrombin: a review. Acta Med Austriaca 2002; 29(3): 89–92

    Article  PubMed  Google Scholar 

  8. White B, Perry D. Acquired antithrombin deficiency in sepsis. Br J Haematol 2001 Jan; 112(1): 26–31

    Article  PubMed  CAS  Google Scholar 

  9. Egeberg O. Inherited fibrinogen abnormality causing thrombophilia. Thromb Diath Haemorrh 1967 Feb 28; 17(1–2): 176–87

    PubMed  CAS  Google Scholar 

  10. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997 Jan; 77(1): 197–211

    PubMed  CAS  Google Scholar 

  11. Hirsh J, Piovella F, Pini M. Congenital antithrombin III deficiency: incidence and clinical features. Am J Med 1989 Sep 11; 87(3B): 34–8S

    Article  Google Scholar 

  12. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975 Jan 16; 292(3): 146–51

    Article  PubMed  CAS  Google Scholar 

  13. Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994 May; 87(1): 106–12

    Article  PubMed  CAS  Google Scholar 

  14. Harper PL, Luddington RJ, Daly M, et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991 Mar; 77(3): 360–4

    Article  PubMed  CAS  Google Scholar 

  15. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism: results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997 Mar; 77(3): 444–51

    PubMed  CAS  Google Scholar 

  16. McColl M, Tait RC, Walker ID, et al. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation. Blood Coagul Fibrinolysis 1996 Oct; 7(7): 689–94

    Article  PubMed  CAS  Google Scholar 

  17. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998 Oct 1; 92(7): 2353–8

    PubMed  CAS  Google Scholar 

  18. Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987 Dec 18; 58(4): 1094

    PubMed  CAS  Google Scholar 

  19. Bushman JE, Palmieri D, Whinna HC, et al. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000 Jul; 24(7): 559–65

    Article  PubMed  CAS  Google Scholar 

  20. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998 Jun; 79(6): 1166–70

    PubMed  CAS  Google Scholar 

  21. Wickstrom K, Edelstam G, Lowbeer CH, et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest 2004; 64(1): 31–40

    Article  PubMed  CAS  Google Scholar 

  22. Morikawa M, Yamada T, Kataoka S, et al. Changes in antithrombin activity and platelet counts in the late stage of twin and triplet pregnancies. Semin Thromb Hemost 2005 Jun; 31(3): 290–6

    Article  PubMed  CAS  Google Scholar 

  23. Tait RC, Walker ID, Islam SI, et al. Influence of demographic factors on antithrombin III activity in a healthy population. Br J Haematol 1993 Jul; 84(3): 476–80

    Article  PubMed  CAS  Google Scholar 

  24. Tormene D, Simioni P, Prandoni P, et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002 Oct 1; 100(7): 2403–5

    Article  PubMed  CAS  Google Scholar 

  25. Franchini M, Veneri D, Salvagno GL, et al. Inherited thrombophilia. Crit Rev Clin Lab Sci 2006; 43(3): 249–90

    Article  PubMed  CAS  Google Scholar 

  26. van Boven HH, Vandenbroucke JP, Westendorp RG, et al. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997 Mar; 77(3): 452–5

    PubMed  Google Scholar 

  27. Sanson BJ, Simioni P, Tormene D, et al. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 1999 Dec 1; 94(11): 3702–6

    PubMed  CAS  Google Scholar 

  28. Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons: report of a large kindred and literature review. Ann Intern Med 1992 May 1; 116(9): 754–61

    PubMed  CAS  Google Scholar 

  29. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006 Jan; 132(2): 171–96

    Article  PubMed  CAS  Google Scholar 

  30. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997 Oct; 78(4): 1183–8

    PubMed  CAS  Google Scholar 

  31. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996 Oct 5; 348(9032): 913–6

    Article  PubMed  CAS  Google Scholar 

  32. Krabbendam I, Franx A, Bots ML, et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2005 Feb 1; 118(2): 143–53

    Article  PubMed  Google Scholar 

  33. Martinez MA, Pena JM, Fernandez A, et al. Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med 1999 Jul; 27(7): 1303–8

    Article  PubMed  CAS  Google Scholar 

  34. Kessler CM, Tang Z, Jacobs HM, et al. The suprapharmacologic dosing of antithrombin concentrate for Staphyiococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997 Jun 15; 89(12): 4393–401

    PubMed  CAS  Google Scholar 

  35. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 Feb 15; 95(4): 1117–23

    PubMed  CAS  Google Scholar 

  36. Greer IA. Thrombophilia: implications for pregnancy outcome. Thromb Res 2003 Jan 25; 109(2–3): 73–81

    Article  PubMed  CAS  Google Scholar 

  37. Paternoster D, Stella A, Simioni P, et al. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet 1994 Dec; 47(3): 215–21

    Article  PubMed  CAS  Google Scholar 

  38. Sayin M, Varol FG, Sayin NC. Evaluation of natural coagulation inhibitor levels in various hypertensive states of pregnancy. Eur J Obstet Gynecol Reprod Biol 2005 Dec 1; 123(2): 183–7

    Article  PubMed  CAS  Google Scholar 

  39. Levy JH, Despotis GJ, Szlam F, et al. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002 May; 96(5): 1095–102

    Article  PubMed  CAS  Google Scholar 

  40. Ranucci M, Ditta A, Boncilli A, et al. Determinants of antithrombin consumption in cardiac operations requiring cardiopulmonary bypass. Perfusion 2004 Jan; 19(1): 47–52

    Article  PubMed  Google Scholar 

  41. Despotis GJ, Filos KS, Zoys TN, et al. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996 Jan; 82(1): 13–21

    PubMed  CAS  Google Scholar 

  42. Ranucci M, Frigiola A, Menicanti L, et al. Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 2005 Feb; 33(2): 355–60

    Article  PubMed  CAS  Google Scholar 

  43. Haemostasis and Thrombosis Task Force BCfSiH. Investigation and management of heritable thrombophilia. Br J Haematol 2001 Sep; 114(3): 512–28

    Article  Google Scholar 

  44. Menache D, O’Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990 Jan 1; 75(1): 33–9

    CAS  Google Scholar 

  45. Lechner K, Kyrle PA. Antithrombin III concentrates: are they clinically useful? Thromb Haemost 1995 Mar; 73(3): 340–8

    PubMed  CAS  Google Scholar 

  46. Konkle BA, Bauer KA, Weinstein R, et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003 Mar; 43(3): 390–4

    Article  PubMed  CAS  Google Scholar 

  47. Bauer KA. Management of thrombophilia. J Thromb Haemost 2003 Jul; 1(7): 1429–34

    Article  PubMed  CAS  Google Scholar 

  48. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005 Sep; 25(9): 1992–7

    Article  PubMed  CAS  Google Scholar 

  49. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 Sep; 126 (3 Suppl.): 627–44S

    Article  Google Scholar 

  50. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005 Jul 15; 106(2): 401–7

    Article  PubMed  CAS  Google Scholar 

  51. McColl MD, Greer IA. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy. Curr Opin Pulm Med 2004 Sep; 10(5): 371–5

    Article  PubMed  CAS  Google Scholar 

  52. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14(2): 127–41

    Article  PubMed  CAS  Google Scholar 

  53. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998 Jul; 24(7): 663–72

    Article  PubMed  CAS  Google Scholar 

  54. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial [erratum appears in JAMA 2002 Jan 9; 287 (2): 192]. JAMA 2001 Oct 17; 286(15): 1869–78

    Article  PubMed  CAS  Google Scholar 

  55. Wiedermann CJ, Hoffmann JN, Juers M, et al. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006 Feb; 34(2): 285–92

    Article  PubMed  CAS  Google Scholar 

  56. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 Jan; 4(1): 90–7

    Article  PubMed  CAS  Google Scholar 

  57. Minneci PC, Deans KJ, Cui X, et al. Antithrombotic therapies for sepsis: a need for more studies. Crit Care Med 2006 Feb; 34(2): 538–41

    Article  PubMed  Google Scholar 

  58. Lemmer JH, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002 Feb; 123(2): 213–7

    Article  PubMed  CAS  Google Scholar 

  59. Williams MR, D’Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000 Sep; 70(3): 873–7

    Article  PubMed  CAS  Google Scholar 

  60. Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005 Jul; 130(1): 107–13

    Article  PubMed  CAS  Google Scholar 

  61. Nomura F, Ihara A, Yoshitatsu M, et al. Relationship between coagulation cascade, cytokine, adhesion molecule and aortic aneurysm. Eur J Cardiothorac Surg 2003 Jun; 23(6): 1034–8

    Article  PubMed  Google Scholar 

  62. Nishiyama T. Antithrombin can modulate coagulation, cytokine production, and expression of adhesion molecules in abdominal aortic aneurysm repair surgery. Anesth Analg 2006 Apr; 102(4): 1007–11

    Article  PubMed  CAS  Google Scholar 

  63. Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving 1-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003 Aug; 90(2): 235–44

    CAS  Google Scholar 

  64. Matsuzaki A, Suminoe A, Hara T. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase. Pediatr Hematol Oncol 2002 Dec; 19(8): 601–3

    Article  PubMed  CAS  Google Scholar 

  65. Morris JD, Harris RE, Hashmi R, et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997 Nov; 20(10): 871–8

    Article  PubMed  CAS  Google Scholar 

  66. Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998 Aug; 158(2): 470–6

    PubMed  CAS  Google Scholar 

  67. Fulia F, Cordaro S, Meo P, et al. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? Biol Neonate 2003; 83(1): 1–5

    Article  PubMed  CAS  Google Scholar 

  68. Edmunds T, Van Patten SM, Pollock J, et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998 Jun 15; 91(12): 4561–71

    PubMed  CAS  Google Scholar 

  69. Lu W, Mant T, Levy JH, et al. Pharmacokinetics of recombinant transgenic antithrombin in volunteers. Anesth Analg 2000 Mar; 90(3): 531–4

    Article  PubMed  CAS  Google Scholar 

  70. Makris M. Safety of antithrombin III concentrate. Blood 1990 Aug 1; 76(3): 649–50

    PubMed  CAS  Google Scholar 

  71. Chang WS, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997 Feb; 77(2): 323–8

    PubMed  CAS  Google Scholar 

  72. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996 May 1; 87(9): 3531–44

    PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Maclean has no conflicts of interest that are directly relevant to the content of this review. Dr Tait has held a consultancy and received honoraria from GTC Biotherapeutics Inc. and is currently principle investigator for a clinical study using recombinant antithrombin, which is sponsored by GTC Biotherapeutics Inc.

Author information

Authors and Affiliations

  1. Department of Haematology, Glasgow Royal Infirmary, 3rd Floor Macewan Building, 84 Castle Street, Glasgow, G4 0SF, UK

    Peter S. Maclean & R. Campbell Tait

Authors
  1. Peter S. Maclean
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Campbell Tait
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter S. Maclean.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maclean, P.S., Tait, R.C. Hereditary and Acquired Antithrombin Deficiency. Drugs 67, 1429–1440 (2007). https://doi.org/10.2165/00003495-200767100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767100-00005

Keywords

Search

Navigation